Bone Biologics Corporation (BBLG)
NASDAQ: BBLG · Real-Time Price · USD
0.8310
-0.0040 (-0.48%)
Apr 2, 2025, 2:41 PM EDT - Market open

Bone Biologics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
-4.11-8.95-1.48-1.61-1.82
Upgrade
Stock-Based Compensation
0.190.150.270.21-
Upgrade
Other Operating Activities
-0.05-0.89-2.180.51
Upgrade
Change in Accounts Payable
0.090.260-0.370.33
Upgrade
Change in Unearned Revenue
--0.780.78--
Upgrade
Change in Other Net Operating Assets
-0.240.66-0.960.050.07
Upgrade
Operating Cash Flow
-4.12-9.56-3.57-1.23-0.43
Upgrade
Short-Term Debt Issued
----0.01
Upgrade
Long-Term Debt Issued
---1.060.39
Upgrade
Total Debt Issued
---1.060.4
Upgrade
Short-Term Debt Repaid
----0.01-
Upgrade
Total Debt Repaid
----0.01-
Upgrade
Net Debt Issued (Repaid)
---1.050.4
Upgrade
Issuance of Common Stock
4.425.044.436.86-
Upgrade
Financing Cash Flow
4.425.044.437.90.4
Upgrade
Net Cash Flow
0.3-4.510.866.68-0.02
Upgrade
Free Cash Flow
-4.12-9.56-3.57-1.23-0.43
Upgrade
Free Cash Flow Per Share
-2.72-36.31-74.84-28.49-8.35
Upgrade
Cash Interest Paid
---0.01-
Upgrade
Levered Free Cash Flow
-2.73-7.21-0.99--
Upgrade
Unlevered Free Cash Flow
-2.73-7.21-0.53--
Upgrade
Change in Net Working Capital
0.281.47-1.49--
Upgrade
Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q